It is now clear that human neoplasms form, progress, and respond to therapy in the context
of an intimate crosstalk with the host immune system. In particular, accumulating evidence …

Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific
stressors, occupies a central position in the development of novel anticancer treatments …

The availability of therapeutics to treat pregnancy complications is severely lacking mainly
because of the risk of causing harm to the fetus. As enhancement of placental growth and …

Tumor-infiltrating lymphocytes (TILs) influence tumor prognosis and the chemotherapeutic
response. Here, we quantified the clinical relevance of TILs, including the effect of TILs on …

Mitotic catastrophe is distinct from other cell death modes due to unique nuclear alterations
characterized as multi and/or micronucleation. Mitotic catastrophe is a common and virtually …

Objective. Because it is uncertain whether immunoglobulin G4–related disease (IgG4-RD) is
associated with malignancy, we evaluated the incidence of cancer development in a large …

Taxanes remain one of the most effective medical treatments for breast cancer. Clinical trials
have coupled taxanes with immune checkpoint inhibitors in patients with triple-negative …

Programmed polyploidization occurs in all mammalian species during development and
aging in selected tissues, but the biological properties of polyploid cells remain obscure …

Necrosis culminates in spilling cellular content through the permeabilized plasma
membrane, thereby releasing potentially immunostimulatory molecules in the pericellular …

Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading
cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination …